Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiological roles in insulin release and glucose homeostasis. The treatment of type 2 diabetes requires positive modulation of GLP-1R to inhibit glucagon secretion and stimulate insulin secretion in a glucose-dependent manner. Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 Å resolution, respectively. The structures reveal a common binding pocket for negative allosteric modulators, present in both GLP-1R and GCGR and located outside helices V-VII near the intracellular half of the receptor. The receptor is in an inactive conformation with compounds that restrict movement of the intracellular tip of helix VI, a movement that is generally associated with activation mechanisms in class A GPCRs. Molecular modelling and mutagenesis studies indicate that agonist positive allosteric modulators target the same general region, but in a distinct sub-pocket at the interface between helices V and VI, which may facilitate the formation of an intracellular binding site that enhances G-protein coupling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this same study, enhanced compound 2 potency was demonstrated by GLP-1R when its residue 332 was mutated to tryptophan, which is in contrast to the effect observed with this mutation on the potency of allosteric antagonists. It was postulated that enhanced compound 2 potency was caused by increased hydrophobic interactions between the receptor and the agonist with this mutation.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [288]
In the citing paper
“Residues 328, 351 and 335 of GLP-1R were recently demonstrated to be important for compound 2 potency, as mutagenesis of these residues reduced compound 2 activity.288”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [288]
Citations
Cites
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Canonical sampling through velocity rescaling
Bussi, G., Donadio, D., & Parrinello, M. (2007) · The Journal of Chemical Physics · doi:10.1063/1.2408420 · Cited by 18,089
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt055 · Cited by 7,473
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006
Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types
Klauda, J. B., Venable, R. M., Freites, J. A., O’Connor, J. W., Tobias, D. J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, A. D., & Pastor, R. W. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp101759q · Cited by 4,501
P-LINCS: A Parallel Linear Constraint Solver for Molecular Simulation
Hess, B. (2008) · Journal of Chemical Theory and Computation · doi:10.1021/ct700200b · Cited by 3,987
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Molecular signatures of G-protein-coupled receptors
Venkatakrishnan, A. J., Deupi, X., Lebon, G., Tate, C. G., Schertler, G. F., & Babu, M. M. (2013) · Nature · doi:10.1038/nature11896 · Cited by 1,497
REFMAC 5 dictionary: organization of prior chemical knowledge and guidelines for its use
Vagin, A. A., Steiner, R. A., Lebedev, A. A., Potterton, L., McNicholas, S., Long, F., & Murshudov, G. N. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904023510 · Cited by 1,350
Crystal structure of opsin in its G-protein-interacting conformation
Scheerer, P., Park, J. H., Hildebrand, P. W., Kim, Y. J., Krauß, N., Choe, H.-W., Hofmann, K. P., & Ernst, O. P. (2008) · Nature · doi:10.1038/nature07330 · Cited by 1,059
Yu, W., He, X., Vanommeslaeghe, K., & MacKerell, A. D. (2012) · Journal of Computational Chemistry · doi:10.1002/jcc.23067 · Cited by 922
Smart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., & Bricogne, G. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911056058 · Cited by 612
FreeSASA: An open source C library for solvent accessible surface area calculations
Mitternacht, S. (2016) · F1000Research · doi:10.12688/f1000research.7931.1 · Cited by 555
Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring
Zhu, K., Borrelli, K. W., Greenwood, J. R., Day, T., Abel, R., Farid, R. S., & Harder, E. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500118s · Cited by 462
Fusion Partner Toolchest for the Stabilization and Crystallization of G Protein-Coupled Receptors
Chun, E., Thompson, A. A., Liu, W., Roth, C. B., Griffith, M. T., Katritch, V., Kunken, J., Xu, F., Cherezov, V., Hanson, M. A., et al. (2012) · Structure · doi:10.1016/j.str.2012.04.010 · Cited by 461
Self-citationStructure of the adenosine A2A receptor bound to an engineered G protein
Carpenter, B., Nehmé, R., Warne, T., Leslie, A. G. W., & Tate, C. G. (2016) · Nature · doi:10.1038/nature18966 · Cited by 435
Structure of class B GPCR corticotropin-releasing factor receptor 1
Hollenstein, K., Kean, J., Bortolato, A., Cheng, R. K. Y., Doré, A. S., Jazayeri, A., Cooke, R. M., Weir, M., & Marshall, F. H. (2013) · Nature · doi:10.1038/nature12357 · Cited by 416
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Self-citationStructure of the human glucagon class B G-protein-coupled receptor
Siu, F. Y., He, M., de Graaf, C., Han, G. W., Yang, D., Zhang, Z., Zhou, C., Xu, Q., Wacker, D., Joseph, J. S., et al. (2013) · Nature · doi:10.1038/nature12393 · Cited by 379
Self-citationTwo disparate ligand-binding sites in the human P2Y1 receptor
Zhang, D., Gao, Z.-G., Zhang, K., Kiselev, E., Crane, S., Wang, J., Paoletta, S., Yi, C., Ma, L., Zhang, W., et al. (2015) · Nature · doi:10.1038/nature14287 · Cited by 365
Self-citationHigh-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875
Srivastava, A., Yano, J., Hirozane, Y., Kefala, G., Gruswitz, F., Snell, G., Lane, W., Ivetac, A., Aertgeerts, K., Nguyen, J., et al. (2014) · Nature · doi:10.1038/nature13494 · Cited by 340
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295
Wootten, D., Simms, J., Miller, L. J., Christopoulos, A., & Sexton, P. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221585110 · Cited by 250
Insights into the structure of class B GPCRs
Hollenstein, K., de Graaf, C., Bortolato, A., Wang, M.-W., Marshall, F. H., & Stevens, R. C. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.001 · Cited by 239
Self-citationSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Self-citationExtra-helical binding site of a glucagon receptor antagonist
Jazayeri, A., Doré, A. S., Lamb, D., Krishnamurthy, H., Southall, S. M., Baig, A. H., Bortolato, A., Koglin, M., Robertson, N. J., Errey, J. C., et al. (2016) · Nature · doi:10.1038/nature17414 · Cited by 216
Structure of the full-length glucagon class B G-protein-coupled receptor
Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., Reedtz-Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., et al. (2017) · Nature · doi:10.1038/nature22363 · Cited by 211
Self-citationA nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db mice
Chen, D., Liao, J., Li, N., Zhou, C., Liu, Q., Wang, G., Zhang, R., Zhang, S., Lin, L., Chen, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610173104 · Cited by 169
Self-citationThe Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
Wootten, D., Reynolds, C. A., Smith, K. J., Mobarec, J. C., Koole, C., Savage, E. E., Pabreja, K., Simms, J., Sridhar, R., Furness, S. G. B., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.023 · Cited by 164
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Cherezov, V., Hanson, M. A., Griffith, M. T., Hilgart, M. C., Sanishvili, R., Venugopalan, N., Stepanov, S. A., Fischetti, R. F., Kühn, P., & Stevens, R. C. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2009.0142.focus · Cited by 156
Self-citationSloop, K. W., Willard, F. S., Brenner, M. B., Ficorilli, J., Valasek, K., Showalter, A. D., Farb, T. B., Cao, J. X. C., Cox, A. L., Michael, M. D., et al. (2010) · Diabetes · doi:10.2337/db10-0689 · Cited by 143
Xiong, Y., Guo, J., Candelore, M. R., Liang, R., Miller, C., Dallas-Yang, Q., Jiang, G., McCann, P. E., Qureshi, S. A., Tong, X., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300579z · Cited by 87
A potentiator of orthosteric ligand activity at GLP-1R acts via covalent modification
Nolte, W. M., Fortin, J.-P., Stevens, B. D., Aspnes, G. E., Griffith, D. A., Hoth, L. R., Ruggeri, R. B., Mathiowetz, A. M., Limberakis, C., Hepworth, D., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1581 · Cited by 86
In vitro expression and analysis of the 826 human G protein-coupled receptors
Lv, X., Liu, J., Shi, Q., Tan, Q., Wu, D., Skinner, J. J., Walker, A. L., Zhao, L., Gu, X.-X., Chen, N., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0263-8 · Cited by 72
Self-citationMathi, S. K., Chan, Y., Li, X., & Wheeler, M. B. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.4.9913 · Cited by 71
Yang, D., de Graaf, C., Yang, L., Song, G., Dai, A., Cai, X., Feng, Y., Reedtz-Runge, S., Hanson, M. A., Yang, H., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721977 · Cited by 60
Self-citationPositive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles
Bueno, A. B., Showalter, A. D., Wainscott, D. B., Stutsman, C., Marín, A., Ficorilli, J., Cabrera, O., Willard, F. S., & Sloop, K. W. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.696039 · Cited by 59
New β-Alanine Derivatives Are Orally Available Glucagon Receptor Antagonists
Lau, J. F., Behrens, C., Sidelmann, U. G., Knudsen, L. B., Lundt, B. F., Sams, C. K., Ynddal, L., Brand, C. L., Pridal, L., Ling, A. L., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm058026u · Cited by 53
Self-citationGuzmán-Pérez, A., Pfefferkorn, J. A., Lee, E. C. Y., Stevens, B. D., Aspnes, G. E., Bian, J., Didiuk, M. T., Filipski, K. J., Moore, D., Perreault, C., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.014 · Cited by 43
Mann, R. J., Al‐Sabah, S., de Maturana, R. L., Sinfield, J. K., & Donnelly, D. (2010) · Peptides · doi:10.1016/j.peptides.2010.09.015 · Cited by 22
Spyridaki, K., Matsoukas, M., Cordomí, A., Gkountelias, K., Papadokostaki, M., Mavromoustakos, T., Logothetis, D. E., Margioris, A. N., Pardo, L., & Liapakis, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.544460 · Cited by 18
Cordomí, A., Ismail, S., Matsoukas, M., Escrieut, C., Ghérardi, M.-J., Pardo, L., & Fourmy, D. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.05.015 · Cited by 16
Patterson, J. T., Li, P., Day, J. W., Gelfanov, V. M., & DiMarchi, R. D. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.01.003 · Cited by 15
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“…critical for signal transduction, have re-energized efforts directed at development of new peptide and small-molecule GLP-1R agonists, including full and biased agonists and allosteric modulators (Figure 5) (Jazayeri et al., 2017; Song et al., 2017; Wootten et al., 2016; Zhang et al., 2017).”
BackgroundInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A positive allosteric modulator binds and activates GLP-1R through binding between helix V and VI, thereby creating an intercellular binding site for the G protein [423].”
BackgroundInfluentialMechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Self-citationG protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Metadata
- Authors
- Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., Liu, D., Wu, F., Wu, Y., Zhao, S., Ye, L., Han, G. W., Lau, J., Wu, B., Hanson, M. A., Liu, Z.-J., Wang, M.-W., & Stevens, R. C.
- Affiliations
- ShanghaiTech University (CN)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- University of Southern California (US)
- Novo Nordisk (Denmark) (DK)
- Kunming Medical University (CN)
- Corresponding author
- Liu, Zhi-Jie
- Wang, Ming-Wei
- Stevens, Raymond C.
- ORCID
- Venue
- Nature
- Published
- 2017-05-17
- Volume
- 546
- Issue
- 7657
- Pages
- 312-315
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2616258954
- Cited by
- 241
- References
- 50
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 18 · 2023: 22 · 2022: 23 · 2021: 27 · 2020: 32 · 2019: 38 · 2018: 31 · 2017: 15
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, transmembrane domain structure, negative allosteric modulators, receptor activation mechanism, class B GPCRs, glucagon receptor, G protein coupling, type 2 diabetes, peptide agonists, glucagon-like peptide-1
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Allosteric Regulation, Allosteric Site, Amino Acid Sequence, Aminopyridines, Benzamides, Humans, Models, Molecular, Phenylurea Compounds, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.